Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... حسب David Henderson (4612354)

Increasing fractions of mobilized and static taxa in the microbial streamwater community, with a corresponding decrease in the fraction of diluted microbial taxa, detail the shift... حسب Dawn R. URycki (9659702)

Supplementary Material for: Allopurinol Use is Associated With Decreased Incidence of Hepatic Decompensation and Overall Mortality Among Individuals With Cirrhosis: a Propensity-ma... حسب figshare admin karger (2628495)

"…Conclusion: In a propensity-score matched analysis of a large national database, individuals with cirrhosis and allopurinol use had significantly lower risk of hepatic decompensation and overall mortality. …"

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. حسب Verónica M. Negrón-Pérez (20691412)

Trends of prevalence (A), incidence (B) deaths (C), and DALYs (D) rates of chronic obstructive pulmonary disease per 100,000 population among adults aged ≥70 years by sex and socio... حسب Kaifang Meng (13848535)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)